GILEAD SCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings (Deprecated 2012-01-31)
GILEAD SCIENCES, INC. (GILD) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings (Deprecated 2012-01-31) of -$40.10 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings · last filed 2012-05-04
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings (deprecated 2012-01-31) for the quarter ending 2012-03-31 was -$40.10M, a 3317.98% decline year-over-year.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $1.67M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $1.71M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $1.62M, a 1312.17% increase year-over-year.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings (deprecated 2012-01-31) for fiscal 2011 was $6.25M, a 5335.65% increase from fiscal 2010.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings (deprecated 2012-01-31) for fiscal 2010 was $115.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings (Deprecated 2012-01-31) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings (Deprecated 2012-01-31) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings (Deprecated 2012-01-31) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | -$40.10M 10-Q · filed 2012-05-04 | -$38.42M derived: sum of 2 quarters · filed 2012-05-04 | -$36.72M derived: sum of 3 quarters · filed 2012-05-04 | -$35.09M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $3.38M derived: sum of 2 quarters · filed 2012-02-23 | $5.00M derived: sum of 3 quarters · filed 2012-02-23 | $6.25M 10-K · filed 2012-02-23 |
| 2011-09-30 | $1.71M 10-Q · filed 2011-11-04 | $3.33M derived: sum of 2 quarters · filed 2011-11-04 | $4.58M 10-Q · filed 2011-11-04 | $4.58M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-06-30 | $1.62M 10-Q · filed 2011-08-05 | $2.87M 10-Q · filed 2011-08-05 | $2.87M derived: sum of 3 quarters · filed 2012-05-04 | $2.87M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-03-31 | $1.25M 10-Q · filed 2012-05-04 | $1.25M derived: sum of 2 quarters · filed 2012-05-04 | $1.25M derived: sum of 3 quarters · filed 2012-05-04 | $1.36M derived: sum of 4 quarters · filed 2012-05-04 |
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $0.00 derived: sum of 2 quarters · filed 2012-02-23 | $115.00K derived: sum of 3 quarters · filed 2012-02-23 | $115.00K 10-K · filed 2012-02-23 |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $115.00K derived: sum of 2 quarters · filed 2011-11-04 | $115.00K 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $115.00K 10-Q · filed 2011-08-05 | $115.00K 10-Q · filed 2011-08-05 | ||
| 2009-06-30 | -$29.00K 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |